IQVIA (IQV) Q3 2026 Earnings Call Transcript
IQVIA reported Q3 2026 revenue of $4.43B, up 8%, with organic growth at 6%. Adjusted EBITDA grew 8.7% to $1.03B, and adjusted EPS rose 11.3% to $3.34. R&D solutions revenue increased 8.7%, and commercial solutions revenue grew 6.9%. The company raised full-year revenue guidance to $17.35B-$17.5B. AI deployments and emerging biopharma funding growth were highlighted.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise are likely to trigger a short‑term price rally, with potential sector‑wide revaluation of CRO firms.
Market read
First‑time disclosure of Q3 2026 earnings and raised guidance makes this a high‑impact earnings event.
What to watch
Higher pass‑through revenue headwinds and foreign‑exchange impacts may temper upside.
Background
IQVIA reported Q3 2026 results, highlighting 8% revenue growth, strong AI adoption, and raised full‑year guidance.
Ticker impact
Q3 2026 earnings beat guidance and full-year revenue and EBITDA forecasts were raised.
upward pressure as investors price in higher revenue and earnings outlook
Revenue and EBITDA guidance were increased by $150M+ and 30M+ respectively, indicating material upside.
Market effects
CRO and health‑tech sector may see broader optimism from IQVIA's AI‑driven growth.
U.S. healthcare services stocks could benefit from spillover sentiment.
International CRO peers may be re‑rated as IQVIA sets a higher growth benchmark.
Counterpoint
If the AI integration costs exceed expectations, margins could compress despite top‑line growth.
Key entities
- ExecutiveAri Bousbib
CEO of IQVIA, quoted on AI adoption driving growth.
- ExecutiveMichael J. Fedock
CFO, discussed pass‑through revenue headwinds.
